Intuitive urge to limit supply and restrict advertising may actually increase access for kids
MedReleaf Corp. (TSX:LEAF) Canada's first and only ISO 9001 and ICH-GMP certified cannabis producer, today announced the introduction of AltaVie by MedReleaf, the Company's premium recreational cannabis brand designed for a premium consumer who is curious, discerning about life in general and searching for physical, mental and emotional enrichment.
Earth Science is making waves in the hemp-derived cannabinoid (CBD), nutraceutical, pharmaceutical and medical device markets.
Maricann Group Inc. (CSE:MARI)(CSE:MARI.CN)(CNSX:MARI), is pleased to provide investors with the following Operational Update post the closing of our recent $40MM financing.
A panel of lawmakers will now hear testimony from some of the state's most experienced advocates for reform. On Thursday morning, the New York State Assembly Standing Committees on Codes, Health, and Alcohol and Drug Abuse will convene a public hearing to discuss the Marijuana Regulation and Taxation Act (MRTA), aimed to legalize the use, distribution, and production of cannabis for adults aged 21 and over.
With Broken Coast, Aphria becomes the largest Canadian EBITDA generating Licensed Producer. Creates leading cross-Canada platform, with scaled low cost greenhouse operations in Ontario and award-winning premium indoor BC production
Aurora Cannabis Inc. (TSX: ACB) (OTCQB: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) and Micron Waste Technologies Inc. (CSE: MWM, OTC: MICWF, Frankfurt: 7FM2), a developer of proprietary digester solutions for the treatment of organic waste, today announced that Aurora has completed a strategic investment in Micron and that the companies have finalized a collaboration agreement pursuant to which both companies will collaborate on the optimization of Micron's technology for the treatment of organic waste generated in the cultivation and production of cannabis products.
MPX Bioceutical Corporation (CSE:MPX) (OTC:MPXEF) today announced that further to its press release dated August 22, 2017, it has entered into a definitive agreement with Panaxia Pharmaceutical Industries Ltd. through its wholly-owned subsidiary Salus BioPharma Corporation, a company engaged in the business of development and production of pharma grade cannabidiol medicinal products, medicinal preparations and medicinal accessories.
Aphria Inc (TSX: APH and US OTC: APHQF) today announced that it has signed a supply agreement with Australian-based Althea Company Pty Ltd. and invested $2.5 million in Althea in exchange for 25% shareholdings in the Company. The investment increases Aphria's presence in the emerging Australian cannabis market.